share_log

Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25

Benzinga ·  Aug 4, 2023 04:32

Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and lowers the price target from $37 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment